文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

Siramesine 可优先诱导银屑病皮损中肥大细胞凋亡

Siramesine causes preferential apoptosis of mast cells in skin biopsies from psoriatic lesions.
PubMed 文献 · Br J Dermatol · 2017-05-15

研究纳入 25 例慢性斑块状银屑病患者,取皮损与非受累皮肤活检,经 siramesine 孵育后分析类胰蛋白酶阳性肥大细胞数量及 IL-6、IL-17 表达,并用流式细胞术评估对成纤维细胞和角质形成细胞的影响。结果显示 siramesine 显著减少皮损与非受累皮肤中肥大细胞总数,降低 IL-6 与 IL-17 阳性肥大细胞密度,对表皮角质形成细胞有抗增殖作用,但对角质形成细胞和真皮成纤维细胞无明显细胞毒作用。

要点

  • siramesine 减少银屑病皮损与非受累皮肤中肥大细胞总数,不改变组织大体形态。
  • siramesine 降低 IL-6 与 IL-17 阳性肥大细胞密度。
  • siramesine 对表皮角质形成细胞有抗增殖作用,对成纤维细胞无明显细胞毒作用。

核心结论

  • siramesine 可优先诱导银屑病皮肤活检中的肥大细胞凋亡,从治疗角度看可能有利。

研究设计与样本

  • 研究纳入 25 例慢性斑块状银屑病患者,取皮损与非受累皮肤进行打孔活检。
  • 活检组织经 siramesine 孵育后分析类胰蛋白酶阳性肥大细胞数量及 IL-6、IL-17 表达。
  • 皮肤活检组织经消化后以流式细胞术分析药物对皮肤成纤维细胞和角质形成细胞的影响。

主要发现

  • siramesine 使皮损与非受累银屑病皮肤活检中肥大细胞总数大幅减少,且不改变组织大体形态。
  • siramesine 降低 IL-6 和 IL-17 阳性肥大细胞的密度。
  • siramesine 对表皮角质形成细胞显示抗增殖作用,但对角质形成细胞或真皮成纤维细胞无明显细胞毒作用。

临床怎么用

  • 基于银屑病病理生理,siramesine 对皮肤肥大细胞的作用可能具有治疗益处。
  • 结果支持进一步研究 siramesine 及其他溶酶体趋向性药物治疗皮肤肥大细胞增多症和由真皮肥大细胞加重的炎症性皮肤病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skin mast cells are implicated as detrimental effector cells in various inflammatory skin diseases such as contact eczema, atopic dermatitis and psoriasis. Selective reduction of cutaneous mast cells, e.g. by inducing targeted apoptosis, might prove a rational and efficient therapeutic strategy in dermatoses negatively influenced by mast cells. OBJECTIVES: The objective of the present study was to evaluate whether a lysosomotropic agent such as siramesine can cause apoptosis of mast cells present in psoriatic lesions. MATERIALS AND METHODS: Punch biopsies were obtained from lesional and uninvolved skin in 25 patients with chronic plaque psoriasis. After incubation with siramesine, the number of tryptase-positive mast cells and their expression of interleukin (IL)-6 and IL-17 was analysed. Skin biopsies were digested to allow flow cytometric analysis of the drug's effect on cutaneous fibroblasts and keratinocytes. RESULTS: Siramesine caused a profound reduction in the total number of mast cells in both lesional and uninvolved psoriatic skin biopsies without affecting the gross morphology of the tissue. The drug reduced the density of IL-6- and IL-17-positive mast cells, and showed antiproliferative effects on epidermal keratinocytes but had no apparent cytotoxic effect on keratinocytes or dermal fibroblasts. CONCLUSIONS: Considering the pathophysiology of psoriasis, the effects of siramesine on cutaneous mast cells may prove favourable from the therapeutic aspect. The results encourage further studies to assess the usefulness of siramesine and other lysosomotropic agents in the treatment of cutaneous mastocytoses and inflammatory skin diseases aggravated by dermal mast cells.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hagforsen E, Lampinen M, Paivandy A, et al. Siramesine causes preferential apoptosis of mast cells in skin biopsies from psoriatic lesions. Br J Dermatol. 2017. PMID: 28117878. doi:10.1111/bjd.15336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。